论文部分内容阅读
目的评价厄贝沙坦(安博维)治疗慢性肾功能不全合并轻中度肾性高血压的降压疗效和安全性。方法慢性肾功能不全(血清肌酐值265～442μmol/L)合并高血压患者40例,给予安博维150mg/d治疗4周,治疗4周末坐位DBP<80mm Hg,且SBP≤130mm Hg者继续原剂量治疗至8周末;坐位DBP>90mm Hg或SBP>140mm Hg者剂量分别加倍至300mg每日1次治疗至8周末。分别观察患者服药前后血压、心率和肝肾功能等生化指标变化及其不良反应。结果 40例患者均完成8周的临床试验。与试验前比较,用药第4周起,患者的收缩压和舒张压均有显著性下降(P<0.05),降压总有效率达85%。不良反应轻而少,试验结束时主要实验室检查指标与试验前比较无统计学差异。结论厄贝沙坦(安博维)150～300mg每日1次是治疗慢性肾功能不全合并轻中度肾性高血压有效药物之一,且安全性好。
Objective To evaluate the antihypertensive efficacy and safety of irbesartan in treating chronic renal insufficiency combined with mild to moderate renal hypertension. Methods 40 patients with chronic renal insufficiency (serum creatinine value 265 ~ 442μmol / L) complicated with hypertension were given Aibowei 150mg / d for 4 weeks. After 4 weeks of treatment, DBP <80mm Hg and SBP≤130mm Hg were continued. The treatment until the 8th weekend; DBP> 90mm Hg or SBP> 140mm Hg doses were doubled to 300mg once daily treatment to 8 weeks. Patients were observed before and after taking blood pressure, heart rate and liver and kidney function and other biochemical changes and adverse reactions. Results All the 40 patients completed 8 weeks clinical trial. Compared with the pre-test, systolic and diastolic blood pressure decreased significantly (P <0.05) and the total effective rate of hypotension was 85% at the 4th week after treatment. Adverse reactions were mild and few. At the end of the experiment, the main laboratory indexes had no statistical difference with those before the test. Conclusion Irbesartan 150 ~ 300mg once daily is one of the effective drugs for treating chronic renal insufficiency combined with mild to moderate renal hypertension, and it is safe.